Home › Compound Library › Brivaracetam (Briviact)

Brivaracetam (Briviact)

Anticonvulsantprescriptionoral · inferred

Prescription antiseizure medicine and high-affinity synaptic vesicle protein 2A (SV2A) ligand used for focal-onset seizures. Oral absorption is rapid and essentially complete, plasma protein binding is low, and elimination is dominated by inactive metabolites formed through non-CYP amide hydrolysis and a smaller CYP2C19-dependent pathway. Adult treatment usually starts at 50 mg twice daily and may be adjusted to 25-100 mg twice daily.

Projected serum levels — 50 mg, twice daily

Brivaracetam (Briviact)
Brivaracetam (Briviact) modeled serum levels, 50 mg twice daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 2 days. 0 25 50 75 100 Day 0 Day 4 Day 7 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 2
Brivaracetam (Briviact) modeled serum levels with a loading dose of 80.6 mg, then 50 mg twice daily The first dose is larger so levels approach steady state faster. 0 25 50 75 100 Day 0 Day 4 Day 7 Day 11 Day 15 Time on a regular schedule

Maintenance schedule: 50 mg twice daily (oral).

Loading schedule: 80.6 mg on day 1, then 50 mg twice daily — reaching therapeutic levels sooner.

Modeled steady state after ~2 days: peak ≈ 74.3 mg, trough ≈ 30.9 mg body load. Population-based estimate over 15 days for a 50 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Anticonvulsant
Route modeled
Oral
Model confidence
inferred
Half-life
9 h
Common dose
50 mg
Suggested maximum
200 mg/day
Reference dose range
25–200 mg (single dose)
Suggested cadence
twice daily
Validated against
50 mg oral — Cmax 1.3 mg/L at 1 h

Research behind this entry

  1. Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects Sargentini-Maier ML et al. · Drug Metabolism and Disposition, 2008 DOI

    Human radiolabel mass-balance study in six healthy men given 150 mg orally. Brivaracetam reached a 4 mg/L peak within 1.5 hours, was 17.5% protein bound, and 96.8% of radioactivity was recovered in urine. Only 8.6% was…

  2. A review of the pharmacology and clinical efficacy of brivaracetam Stephen LJ, Brodie MJ · Therapeutic Advances in Neurological Disorders, 2018 DOI

    Clinical review describing brivaracetam's higher SV2A affinity than levetiracetam, rapid linear pharmacokinetics, approximately 7-9 hour half-life, regulatory trials, and its role as adjunctive treatment for focal-onset…

  3. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial Biton V et al. · Epilepsia, 2014 DOI

    In a 12-week randomized trial, adjunctive brivaracetam 50 mg/day reduced baseline-adjusted focal-seizure frequency by 12.8% over placebo on the prespecified weekly analysis (p=0.025); 5 and 20 mg/day did not meet that…

  4. Efficacy, safety, and tolerability of adjunctive brivaracetam in adult Asian patients with uncontrolled focal-onset seizures: A phase III randomized, double-blind, placebo-controlled trial. Inoue Y, Tiamkao S, Zhou D, Cabral-Lim L, Lim KS, Lim SH, Tsai JJ, Moseley B, Wang L, Sun W, Hayakawa Y, Sasamoto H, Sano T, McClung C, Bass A · Epilepsia open, 2024 DOI

    This citation reports a human clinical study involving Brivaracetam (Briviact). It does not by itself establish a qualified dose, safety profile, efficacy claim, or pharmacokinetic route for this record.

4 published studies referenced in the app, each with a plain-language summary.